These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. How to eliminate HCV infection by antiviral treatment. Martin NK; Vickerman P; Hickman M J Hepatol; 2017 Jul; 67(1):5-6. PubMed ID: 28323120 [No Abstract] [Full Text] [Related]
6. In DAA We Trust: Key Factors Essential to HCV Elimination. Burton MJ Dig Dis Sci; 2019 Oct; 64(10):2701-2702. PubMed ID: 31388855 [No Abstract] [Full Text] [Related]
7. Prevention and management of treatment failure to new oral hepatitis C drugs. Benítez-Gutiérrez L; Barreiro P; Labarga P; de Mendoza C; Fernandez-Montero JV; Arias A; Peña JM; Soriano V Expert Opin Pharmacother; 2016 Jun; 17(9):1215-23. PubMed ID: 27149603 [TBL] [Abstract][Full Text] [Related]
8. Uptake of direct-acting antiviral treatment for chronic hepatitis C in Australia. Hajarizadeh B; Grebely J; Matthews GV; Martinello M; Dore GJ J Viral Hepat; 2018 Jun; 25(6):640-648. PubMed ID: 29274192 [TBL] [Abstract][Full Text] [Related]
9. [Prescription of new HCV-drugs - what has to be considered judicially]. Mauss S Z Gastroenterol; 2015 Jan; 53(1):43-5. PubMed ID: 25594707 [TBL] [Abstract][Full Text] [Related]
11. A case of acute hepatitis B in a chronic hepatitis C patient after daclatasvir and asunaprevir combination therapy: hepatitis B virus reactivation or acute self-limited hepatitis? Hayashi K; Ishigami M; Ishizu Y; Kuzuya T; Honda T; Nishimura D; Goto H; Hirooka Y Clin J Gastroenterol; 2016 Aug; 9(4):252-6. PubMed ID: 27329484 [TBL] [Abstract][Full Text] [Related]
12. Successful direct acting antiviral (DAA) treatment of HCV/HIV-coinfected patients before and after liver transplantation. Grottenthaler JM; Werner CR; Steurer M; Spengler U; Berg T; Engelmann C; Wedemeyer H; von Hahn T; Stremmel W; Pathil A; Seybold U; Schott E; Blessin U; Sarrazin C; Welker MW; Harrer E; Scholten S; Hinterleitner C; Lauer UM; Malek NP; Berg CP PLoS One; 2018; 13(6):e0197544. PubMed ID: 29874250 [TBL] [Abstract][Full Text] [Related]
13. Hepatocellular carcinoma decreases the chance of successful hepatitis C virus therapy with direct-acting antivirals. Prenner SB; VanWagner LB; Flamm SL; Salem R; Lewandowski RJ; Kulik L J Hepatol; 2017 Jun; 66(6):1173-1181. PubMed ID: 28161470 [TBL] [Abstract][Full Text] [Related]
14. [Current management of hepatitis C]. Lange CM Med Monatsschr Pharm; 2015 Sep; 38(9):337-44; quiz 345-6. PubMed ID: 26731851 [TBL] [Abstract][Full Text] [Related]
15. A population approach to disease management: hepatitis C direct-acting antiviral use in a large health care system. Belperio PS; Backus LI; Ross D; Neuhauser MM; Mole LA J Manag Care Spec Pharm; 2014 Jun; 20(6):533-40. PubMed ID: 24856591 [TBL] [Abstract][Full Text] [Related]
16. Direct-Acting Antiviral Therapy Restores Immune Tolerance to Patients With Hepatitis C Virus-Induced Cryoglobulinemia Vasculitis. Comarmond C; Garrido M; Pol S; Desbois AC; Costopoulos M; Le Garff-Tavernier M; Si Ahmed SN; Alric L; Fontaine H; Bellier B; Maciejewski A; Rosenzwajg M; Klatzmann D; Musset L; Poynard T; Cacoub P; Saadoun D Gastroenterology; 2017 Jun; 152(8):2052-2062.e2. PubMed ID: 28274850 [TBL] [Abstract][Full Text] [Related]